Moran Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Moran Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-180,915	Closed	-$5.69M	–	510
2026 Q2	$5.69M	Buy	180,915 +11,954	+7%	+$353K	0.16%	197
2026 Q1	$4.18M	Buy	168,961 +137,791	+442%	+$3.28M	0.13%	218
2025 Q4	$728K	Buy	31,170 +4,998	+19%	+$111K	0.02%	374
2025 Q3	$516K	Sell	26,172 -7,263	-22%	-$149K	0.02%	403
2025 Q2	$726K	Buy	33,435 +2,225	+7%	+$52.5K	0.02%	355
2025 Q1	$757K	Buy	31,210 +21,135	+210%	+$476K	0.03%	329
2024 Q4	$210K	Buy	+10,075	New	+$216K	0.01%	402

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Moran Wealth Management's CPRX Position: Q3 2026 in Review

Moran Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 180,915 shares — an estimated $5.69M sold.

Moran Wealth Management first reported a position in CPRX in Q4 2024 and held it in 7 quarters. The position peaked at $5.69M in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Moran Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Moran Wealth Management sold 180,915 Catalyst Pharmaceutical shares in Q3 2026, an estimated $5.69M.
Moran Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 7 quarters.
Moran Wealth Management's Catalyst Pharmaceutical position peaked at $5.69M in Q2 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Moran Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.